1. Volume 73, Issue 6, Pages 961-967 (June 2018)
Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening 
Melissa Assel, Anders Dahlin, David Ulmert, Anders Bergh, Pär Stattin, Hans Lilja, Andrew J. Vickers 
European Urology 
Volume 73, Issue 6, Pages (June 2018)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
Flow diagram of the inclusion process for the Malmö Preventive Project (MPP) and the Malmö Diet and Cancer (MDC) cohorts. PSA, prostate-specific antigen.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

3. Fig. 2
Flow diagram of the inclusion process for the Västerbotten Intervention Project (VIP) cohort. PSA, prostate-specific antigen.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

4. Fig. 3
Probability of high-grade (solid line) and low-grade (dashed line) prostate cancer by lead time among participants aged 45–70 yr with prostate-specific antigen of 3.0–10 ng/ml at baseline blood draw. The shaded area denotes the shape of the distribution of lead times rescaled for presentation. PCa, prostate cancer; PSA, prostate-specific antigen.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions